Home › Companies › RIGEL PHARMACEUTICALS INC. › 2023-2024

RIGEL PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Compiled from SEC Form N-PX filings and RIGEL PHARMACEUTICALS INC.’s Form 8-K, filed 2024-05-29 (Item 5.07 on EDGAR). Page generated 02 October 2026.

7Reported items
128Asset managers
1,011Fund votes
2024-05-24Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore RIGEL PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by RIGEL PHARMACEUTICALS INC.

These tallies are RIGEL PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2024-05-29 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

RIGEL PHARMACEUTICALS INC. — official shareholder meeting results, meeting held 2024-05-24
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Brian L. Kotzin	78,451,723	--	1,529,351	24,372,506	26,314,869	Majority: yes
Elect Director: Gregg A. Lapointe	79,150,066	--	1,525,575	23,677,939	26,314,869	Majority: yes
Approval of the Amended 2018 Plan The Company's stockholders approved the Amended 2018 Plan.	53,147,924	48,240,156	2,965,500	--	26,314,869	Majority: yes
Say-on-Pay The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.	74,738,206	26,220,078	3,395,296	--	26,314,869	Majority: yes

Source: RIGEL PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2024-05-29 — read the filing on EDGAR.

How asset managers voted at the RIGEL PHARMACEUTICALS INC. 2023-2024 meeting

Each item below shows how the 128 asset managers that disclosed a RIGEL PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of RIGEL PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%AGAINST 26%

FOR: 74,738,206AGAINST: 26,220,078

RIGEL PHARMACEUTICALS INC.’s own tally for this item (“Say-on-Pay The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”): 74,738,206 for, 26,220,078 against, per its Form 8-K filed 2024-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 175,406,146 outstanding shares: 43% for, 15% against (58% of the company cast a for/against vote).

The 127 asset managers below cast 84% of the shares they voted on this item FOR (78,039,810 for, 14,796,569 against).

FOR 84%AGAINST 16%

FOR: 78,039,810 (84.0%)AGAINST: 14,796,569 (15.9%)ABSTAIN: 88,669 (0.1%)

Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at RIGEL PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Vote
ARMISTICE CAPITAL, LLC	0	14,014,448	Against
BlackRock	13,584,758	0	For
Vanguard	9,357,360	0	For
Soleus Capital Management, L.P.	9,241,986	0	For
Fidelity	3,994,935	0	For
GEODE CAPITAL MANAGEMENT, LLC	3,792,499	0	For
State Street	3,215,606	0	For
Voya	3,110,048	0	For
Nuveen	2,864,150	0	For
TIAA	2,854,841	0	For
ACADIAN ASSET MANAGEMENT LLC	2,290,327	0	For
JACOBS LEVY EQUITY MANAGEMENT, INC	2,118,241	0	For
Ensign Peak Advisors, Inc	2,034,204	0	For
Delaware/Macquarie	1,600,000	0	For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST	1,600,000	0	For
Charles Schwab	1,487,230	0	For
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	1,359,200	0	For
Northern Trust	1,352,042	160	For
Renaissance	1,093,800	0	For
Stonepine Capital Management, LLC	1,040,241	0	For
SEI	953,417	0	For
MELLON INVESTMENTS Corp	738,305	0	For
Two Sigma	724,975	0	For
Wellington	673,325	0	For
UBS	672,750	45	For

Showing the 25 largest of 127 asset managers. See all 127 in the interactive database.

2. Election of Directors: Brian L. Kotzin

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

76% Majority: yes · of votes cast

FOR 76%WITHHELD 24%

FOR: 78,451,723WITHHELD: 24,372,506

RIGEL PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Brian L. Kotzin”): 78,451,723 for, 24,372,506 withheld, per its Form 8-K filed 2024-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 175,406,146 outstanding shares: 45% for, 14% withheld (59% of the company cast a for/withheld vote).

The 44 asset managers below cast 99% of the shares they voted on this item FOR (29,062,828 for, 341,735 against).

FOR 99%

FOR: 29,062,828 (98.5%)AGAINST: 341,735 (1.2%)ABSTAIN: 88,669 (0.3%)

Largest asset managers voting on “Election of Directors: Brian L. Kotzin” at RIGEL PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	9,061,718	0	0	For
BlackRock	6,943,627	0	0	For
Fidelity	3,795,417	0	0	For
TIAA	2,854,841	0	0	For
Delaware/Macquarie	1,600,000	0	0	For
Voya	1,305,129	0	0	For
Charles Schwab	743,615	0	0	For
Equitable	295,130	314,730	0	Against
BRIDGEWAY FUNDS INC	521,200	0	0	For
SEI	475,477	0	0	For
QUANTITATIVE MASTER SERIES LLC	305,297	0	0	For
Lincoln Financial	147,363	0	0	For
Brighthouse	56,766	0	88,669	Abstain
Northern Trust	75,696	0	0	For
Nationwide	74,467	0	0	For
T. Rowe Price	74,332	0	0	For
John Hancock	67,421	0	0	For
Legg Mason	66,563	0	0	For
Goldman Sachs	60,610	0	0	For
Pacific Life	57,810	0	0	For
Russell Investments	51,654	0	0	For
AIG/SunAmerica	45,437	0	0	For
Principal Exchange-Traded Funds	39,688	0	0	For
Bridge Builder Trust	35,340	0	0	For
PFM Multi-Manager Series Trust	34,403	0	0	For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

3. Election of Directors: Gregg A. Lapointe

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

77% Majority: yes · of votes cast

FOR 77%WITHHELD 23%

FOR: 79,150,066WITHHELD: 23,677,939

RIGEL PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Gregg A. Lapointe”): 79,150,066 for, 23,677,939 withheld, per its Form 8-K filed 2024-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 175,406,146 outstanding shares: 45.1% for, 13% withheld (59% of the company cast a for/withheld vote).

The 44 asset managers below cast 99% of the shares they voted on this item FOR (29,075,023 for, 329,540 against).

FOR 99%

FOR: 29,075,023 (98.6%)AGAINST: 329,540 (1.1%)ABSTAIN: 88,669 (0.3%)

Largest asset managers voting on “Election of Directors: Gregg A. Lapointe” at RIGEL PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	9,061,718	0	0	For
BlackRock	6,943,627	0	0	For
Fidelity	3,795,417	0	0	For
TIAA	2,854,841	0	0	For
Delaware/Macquarie	1,600,000	0	0	For
Voya	1,305,129	0	0	For
Charles Schwab	743,615	0	0	For
Equitable	295,130	314,730	0	Against
BRIDGEWAY FUNDS INC	521,200	0	0	For
SEI	475,477	0	0	For
QUANTITATIVE MASTER SERIES LLC	305,297	0	0	For
Lincoln Financial	147,363	0	0	For
Brighthouse	56,766	0	88,669	Abstain
Northern Trust	75,696	0	0	For
Nationwide	74,467	0	0	For
T. Rowe Price	74,332	0	0	For
John Hancock	67,421	0	0	For
Legg Mason	66,563	0	0	For
Goldman Sachs	60,610	0	0	For
Pacific Life	57,810	0	0	For
Russell Investments	51,654	0	0	For
AIG/SunAmerica	45,437	0	0	For
Principal Exchange-Traded Funds	39,688	0	0	For
Bridge Builder Trust	35,340	0	0	For
PFM Multi-Manager Series Trust	34,403	0	0	For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

4. To approve an amendment to our 2018 Equity Incentive Plan, as amended (the "Amended 2018 Plan"), to add an additional 6,500,000 shares to the number of shares of common stock authorized for issuance under the Amended 2018 Plan.

COMPENSATIONMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

52.4% Majority: yes · of votes cast

FOR 52.4%AGAINST 47.6%

FOR: 53,147,924AGAINST: 48,240,156

RIGEL PHARMACEUTICALS INC.’s own tally for this item (“Approval of the Amended 2018 Plan The Company's stockholders approved the Amended 2018 Plan.”): 53,147,924 for, 48,240,156 against, per its Form 8-K filed 2024-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 175,406,146 outstanding shares: 30% for, 28% against (58% of the company cast a for/against vote).

The 44 asset managers below cast 83% of the shares they voted on this item FOR (24,524,201 for, 4,880,362 against).

FOR 83%AGAINST 17%

FOR: 24,524,201 (83.2%)AGAINST: 4,880,362 (16.5%)ABSTAIN: 88,669 (0.3%)

Largest asset managers voting on “To approve an amendment to our 2018 Equity Incentive Plan, as amended (the "Amended 2018 Plan"), to add an add” at RIGEL PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	9,061,718	0	0	For
BlackRock	6,943,627	0	0	For
Fidelity	3,605,770	189,647	0	For
TIAA	2,854,841	0	0	For
Delaware/Macquarie	0	1,600,000	0	Against
Voya	0	1,305,129	0	Against
Charles Schwab	743,615	0	0	For
Equitable	295,130	314,730	0	Against
BRIDGEWAY FUNDS INC	0	521,200	0	Against
SEI	475,477	0	0	For
QUANTITATIVE MASTER SERIES LLC	305,297	0	0	For
Lincoln Financial	0	147,363	0	Against
Brighthouse	0	56,766	88,669	Abstain
Northern Trust	0	75,696	0	Against
Nationwide	0	74,467	0	Against
T. Rowe Price	0	74,332	0	Against
John Hancock	0	67,421	0	Against
Legg Mason	0	66,563	0	Against
Goldman Sachs	0	60,610	0	Against
Pacific Life	57,810	0	0	For
Russell Investments	51,654	0	0	For
AIG/SunAmerica	0	45,437	0	Against
Principal Exchange-Traded Funds	0	39,688	0	Against
Bridge Builder Trust	35,340	0	0	For
PFM Multi-Manager Series Trust	0	34,403	0	Against

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

5. TO APPROVE AN AMENDMENT TO THE COMPANY'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT OF COMMON STOCK (WITHOUT REDUCING THE AUTHORIZED NUMBER OF SHARES OF COMMON STOCK), IF AND WHEN DETERMINED BY THE COMPANY'S BOARD OF DIRECTORS.

CAPITAL STRUCTURE

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.6%

The 44 asset managers below cast 100% of the shares they voted on this item FOR (29,404,563 for, 0 against).

FOR: 29,404,563 (99.7%)ABSTAIN: 88,669 (0.3%)

Largest asset managers voting on “TO APPROVE AN AMENDMENT TO THE COMPANY'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE” at RIGEL PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	9,061,718	0	For
BlackRock	6,943,627	0	For
Fidelity	3,795,417	0	For
TIAA	2,854,841	0	For
Delaware/Macquarie	1,600,000	0	For
Voya	1,305,129	0	For
Charles Schwab	743,615	0	For
Equitable	609,860	0	For
BRIDGEWAY FUNDS INC	521,200	0	For
SEI	475,477	0	For
QUANTITATIVE MASTER SERIES LLC	305,297	0	For
Lincoln Financial	147,363	0	For
Brighthouse	56,766	88,669	Abstain
Northern Trust	75,696	0	For
Nationwide	74,467	0	For
T. Rowe Price	74,332	0	For
John Hancock	67,421	0	For
Legg Mason	66,563	0	For
Goldman Sachs	60,610	0	For
Pacific Life	57,810	0	For
Russell Investments	51,654	0	For
AIG/SunAmerica	45,437	0	For
Principal Exchange-Traded Funds	39,688	0	For
Bridge Builder Trust	35,340	0	For
PFM Multi-Manager Series Trust	34,403	0	For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

6. TO APPROVE THE ADJOURNMENT OF THE ANNUAL MEETING TO A LATER DATE OR DATES, IF NECESSARY, TO PERMIT FURTHER SOLICITATION AND VOTE OF PROXIES IN THE EVENT THERE ARE NOT SUFFICIENT VOTES IN FAVOR OF THE AMENDMENT TO THE COMPANY'S AMENDED AND RESTATED CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT.

CORPORATE GOVERNANCE

Combines 2 wordings of this item as funds reported it.

99.0% fund support · no official result

FOR 99%

The 44 asset managers below cast 99.0% of the shares they voted on this item FOR (29,133,784 for, 270,779 against).

FOR: 29,133,784 (98.8%)AGAINST: 270,779 (0.9%)ABSTAIN: 88,669 (0.3%)

Largest asset managers voting on “TO APPROVE THE ADJOURNMENT OF THE ANNUAL MEETING TO A LATER DATE OR DATES, IF NECESSARY, TO PERMIT FURTHER SOL” at RIGEL PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Against	Abstain	Vote
Vanguard	9,061,718	0	0	For
BlackRock	6,943,627	0	0	For
Fidelity	3,795,417	0	0	For
TIAA	2,854,841	0	0	For
Delaware/Macquarie	1,600,000	0	0	For
Voya	1,305,129	0	0	For
Charles Schwab	743,615	0	0	For
Equitable	609,860	0	0	For
BRIDGEWAY FUNDS INC	521,200	0	0	For
SEI	475,477	0	0	For
QUANTITATIVE MASTER SERIES LLC	305,297	0	0	For
Lincoln Financial	0	147,363	0	Against
Brighthouse	56,766	0	88,669	Abstain
Northern Trust	75,696	0	0	For
Nationwide	74,467	0	0	For
T. Rowe Price	0	74,332	0	Against
John Hancock	67,421	0	0	For
Legg Mason	66,563	0	0	For
Goldman Sachs	60,610	0	0	For
Pacific Life	57,810	0	0	For
Russell Investments	51,654	0	0	For
AIG/SunAmerica	45,437	0	0	For
Principal Exchange-Traded Funds	39,688	0	0	For
Bridge Builder Trust	35,340	0	0	For
PFM Multi-Manager Series Trust	34,403	0	0	For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

7. TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2024.

AUDIT-RELATED

Combines 2 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.6%

The 44 asset managers below cast 100% of the shares they voted on this item FOR (29,404,563 for, 0 against).

FOR: 29,404,563 (99.7%)ABSTAIN: 88,669 (0.3%)

Largest asset managers voting on “TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPA” at RIGEL PHARMACEUTICALS INC., 2023-2024
Asset manager	For	Abstain	Vote
Vanguard	9,061,718	0	For
BlackRock	6,943,627	0	For
Fidelity	3,795,417	0	For
TIAA	2,854,841	0	For
Delaware/Macquarie	1,600,000	0	For
Voya	1,305,129	0	For
Charles Schwab	743,615	0	For
Equitable	609,860	0	For
BRIDGEWAY FUNDS INC	521,200	0	For
SEI	475,477	0	For
QUANTITATIVE MASTER SERIES LLC	305,297	0	For
Lincoln Financial	147,363	0	For
Brighthouse	56,766	88,669	Abstain
Northern Trust	75,696	0	For
Nationwide	74,467	0	For
T. Rowe Price	74,332	0	For
John Hancock	67,421	0	For
Legg Mason	66,563	0	For
Goldman Sachs	60,610	0	For
Pacific Life	57,810	0	For
Russell Investments	51,654	0	For
AIG/SunAmerica	45,437	0	For
Principal Exchange-Traded Funds	39,688	0	For
Bridge Builder Trust	35,340	0	For
PFM Multi-Manager Series Trust	34,403	0	For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

Largest RIGEL PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked by the number of RIGEL PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2023-2024 meeting, shown as a share of the 175,406,146 shares outstanding at the time of that meeting.

Top RIGEL PHARMACEUTICALS INC. shareholders by shares voted, 2023-2024
#	Asset manager	% of shares outstanding
1	ARMISTICE CAPITAL, LLC	7.99%
2	BlackRock	7.74%
3	Vanguard	5.33%
4	Soleus Capital Management, L.P.	5.27%
5	Fidelity	2.28%
6	GEODE CAPITAL MANAGEMENT, LLC	2.16%
7	State Street	1.83%
8	Voya	1.77%
9	Nuveen	1.63%
10	TIAA	1.63%

Reported RIGEL PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

RIGEL PHARMACEUTICALS INC. beneficial owners on record for the 2023-2024 proxy season
Holder	% outstanding	Disclosure
The Vanguard Group	5.10%	13G
Geode Capital	2.16%	13F
State Street	2.13%	13F
Nuveen	1.84%	13F
Renaissance Technologies	1.15%	13F
Millennium Management	1.07%	13F
Northern Trust	0.83%	13F
Wellington Management	0.48%	13F
Charles Schwab	0.42%	13F
BNY Mellon	0.30%	13F

Percentages above are of 175,406,146 shares outstanding, as reported by RIGEL PHARMACEUTICALS INC. on its Form 10-Q dated 2024-05-02 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from RIGEL PHARMACEUTICALS INC.’s 10-Q dated 2024-05-02. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At RIGEL PHARMACEUTICALS INC.'s shareholder meeting held 2024-05-24, in the 2023-2024 proxy season, 128 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,011 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — FOR was 74% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: RIGEL PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2024-05-29.

RIGEL PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.